Serina Therapeutics(SER)

Focus: Serina Therapeutics is a public biotech company founded in 1967 focused on small molecules attached to polymers for neurology indications, currently operating as a pre-revenue stage company.

Neurology

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Serina Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Serina Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$56K

Pipeline & Clinical Trials

SER-252

PARKINSON DISEASE (Disorder)

PHASE_1

Clinical Trials (1)

NCT07422675SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

Phase 1

Help build intelligence for Serina Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage neurology focus with novel polymer-conjugate platform technology in nascent Parkinson's disease space
Public company status provides liquidity and institutional visibility versus private equivalents
Active research pipeline with two Phase 1 programs (SER-252, SER-214) offers hands-on drug development experience

Watch Out For

Severe cash burn: $11.1M net loss in FY 2025 with only $4M cash remaining and minimal revenue ($56K), creating 4-6 month runway risk
Zero open positions currently listed and no active hiring, signaling potential hiring freeze or structural challenges
Pre-revenue status with only Phase 1 programs means 5-7+ years minimum to commercial catalyst; significant execution and capital risk

Generated by Claude from Serina Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

SER-214

Parkinson's Disease

PHASE_1

Clinical Trials (1)

NCT02579473A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 1967

Portfolio: 2 clinical trials

Top TAs: Neurology

Publications: 6 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Neurology

2 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$56K98%

R&D Spend

$7M(13357%)213%

Net Income

-$11M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(6)

Recent peer-reviewed publications with author affiliations at this company

Expert insights into the development of large-volume subcutaneous drugs with permeation enhancers: A survey examining challenges, alternatives, and future directions.

International journal of pharmaceutics

2026

PMID:41418838

Insights from a Survey of Drug Formulation Experts: Challenges and Preferences in High-Concentration Subcutaneous Biologic Drug Development.